Eli Lilly & Co. and AstraZeneca Plc ended two late-stage trials of an experimental drug for Alzheimer’s disease after the treatment failed to show any signs of working, adding to a litany of disappointments for the memory-robbing illness.
An independent data monitoring committee found that the medicine, lanabecestat, was unlikely to meet the goals of the studies, one for early Alzheimer’s and the other for mild dementia related to the disease, the companies said in a statement Tuesday.
More from Bloomberg.com: Brace for the World Economy’s Most Important Week of the Year
Like several others that failed, such as Merck & Co.’s verubecestat, the drug targeted a protein called amyloid, thought to be a cause of the disease. The class of medicines known as BACE inhibitors operate before the amyloid has formed into deposits, called plaques. Many researchers now believe that administering drugs after amyloid has built up in the brain may come too late to affect Alzheimer’s progress.
“The complexity of Alzheimer’s disease poses one of the most difficult medical challenges of our time, and we are deeply disappointed for the millions suffering from this devastating disease,” Daniel Skovronsky, president of Lilly Research Labs, said in the statement.
More from Bloomberg.com: Kudlow Is 'Doing Well' After Mild Heart Attack, White House Says
The decision to end the trials won’t have a material financial impact on AstraZeneca, and its guidance for this year remains unchanged, the Cambridge, England-based company said in a separate statement. Lilly doesn’t anticipate significant costs associated with the end of the studies and reaffirmed its financial guidance for 2018 and its mid-term guidance for the remainder of the decade.
By one count, more than 190 Alzheimer drugs have failed in trials. Spending on care for people alive in the U.S. right now who will develop the affliction is projected to cost $47 trillion over the course of their lives, according to a report in March from the Alzheimer’s Association. The U.S. is projected to spend $277 billion on Alzheimer’s or other dementia care in 2018 alone, with an aging cohort of baby boomers pushing that number to $1.1 trillion by 2050.
More from Bloomberg.com: Cryptocurrencies Lose $42 Billion After South Korean Bourse Hack
The studies weren’t halted due to safety concerns. Instead, the data-monitoring committee advised stopping for futility.
AstraZeneca shares fell 0.5 percent in London, trading at 5,340 pence at 8:40 a.m. Lilly closed at $85.86 yesterday in New York.
More from Bloomberg.com
- How Canada's Sacred Cows and 270% Tariffs Set Trump Off at G-7
- Kim Jong Un Surprises Crowds in Singapore With Late-Night Tour
- Trump-Kim Handshake to Open Summit With Outcome Hanging in Balance
Read Another Alzheimer's Drug Fails as Lilly, Astra Halt Tests on bloomberg.com